Search results for "MESH : Remission Induction"

showing 1 items of 1 documents

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

MaleMESH: Remission InductionMESH : Retrospective StudiesMESH : RecurrenceMESH: Leukemia MyeloidMESH: Length of StayRecurrence[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : FemaleHospital Costshealth care economics and organizationsMESH: Diagnosis-Related GroupsMESH: Hospital CostsMESH: Middle AgedRemission InductionMESH : Acute DiseaseMiddle AgedMESH : AdultMESH : Diagnosis-Related GroupsMESH : Length of StayLeukemia MyeloidAcute DiseaseMESH : Leukemia MyeloidMESH: Acute Disease[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMESH : Prospective Payment SystemFranceAdultAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : MaleMESH : Hospital CostsMESH: Prospective Payment SystemMESH : AdolescentHumansMESH : Middle AgedMESH : FranceDiagnosis-Related GroupsRetrospective StudiesMESH: AdolescentMESH : Remission InductionMESH: HumansProspective Payment SystemMESH : HumansMESH: Retrospective StudiesMESH: AdultLength of StayMESH: MaleMESH: RecurrenceMESH: FranceMESH: Female
researchProduct